Case File №
#VI-2026-0812
Orbitrex Peptides
Vendor-Supplied Policies
Exhibit I
Compounds on File
39 LINE ITEMS| Compound | Grade | Samples | Mean | Min | Max | Latest |
|---|---|---|---|---|---|---|
| GHK-Cu | A Great | 2 | 9.1 | 9.0 | 9.2 | 25 Oct 2025 |
| Retatrutide | A Great | 9 | 8.8 | 6.5 | 10.0 | 7 Oct 2025 |
| Tirzepatide | A Great | 3 | 8.8 | 8.2 | 9.2 | 23 Nov 2025 |
| 1-Boc-4-AP (tert-butyl 4-(phenylamino)piperidine-1-carboxylate) CAS 125541-22-2 | X N/A | 1 | 8.3 | 8.3 | 8.3 | 14 Jan 2025 |
| (2-Chloroethyl)benzene CAS 622-24-2 | X N/A | 1 | 8.7 | 8.7 | 8.7 | 9 Jun 2025 |
| ACE-031 | X N/A | 1 | 9.3 | 9.3 | 9.3 | 11 Jun 2025 |
| Adamax | X N/A | 1 | 7.1 | 7.1 | 7.1 | 24 Apr 2025 |
| Adipotide | X N/A | 1 | 9.3 | 9.3 | 9.3 | 6 May 2025 |
| Anastrozole (Arimidex) Raw | X N/A | 1 | 7.3 | 7.3 | 7.3 | 20 Jun 2025 |
| BAM15 | X N/A | 1 | 7.2 | 7.2 | 7.2 | 13 Jun 2025 |
| Cagrilintide 5mg + Semaglutide 5mg Blend | X N/A | 1 | 8.0 | 8.0 | 8.0 | 3 Jul 2025 |
| Cerebrolysin | X N/A | 1 | 9.9 | 9.9 | 9.9 | 13 Feb 2025 |
| CJC-1295 With DAC | X N/A | 1 | 6.8 | 6.8 | 6.8 | 9 Jun 2025 |
| Dianabol | X N/A | 1 | 7.0 | 7.0 | 7.0 | 14 Jan 2025 |
| EAPA (ethyl alpha-phenylacetoacetate / ethyl 3-oxo-2-phenylbutanoate) CAS 5413-05-8 | X N/A | 1 | 6.4 | 6.4 | 6.4 | 2 Apr 2025 |
| Enclomiphene | X N/A | 1 | 10.0 | 10.0 | 10.0 | 21 May 2025 |
| EPO | X N/A | 1 | 10.0 | 10.0 | 10.0 | 8 Jul 2025 |
| GHRP-2 Acetate | X N/A | 1 | 10.0 | 10.0 | 10.0 | 11 Jun 2025 |
| GLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg | X N/A | 1 | 6.4 | 6.4 | 6.4 | 16 Mar 2025 |
| Glutathione | X N/A | 1 | 5.9 | 5.9 | 5.9 | 27 Feb 2025 |
| Halotestin (Fluoxymesterone) | X N/A | 1 | 6.8 | 6.8 | 6.8 | 9 Jun 2025 |
| Hyaluronic acid | X N/A | 1 | 10.0 | 10.0 | 10.0 | 13 Jun 2025 |
| IGF-1 LR3 | X N/A | 1 | 9.7 | 9.7 | 9.7 | 8 Jul 2025 |
| KissPeptin-10 | X N/A | 1 | 10.0 | 10.0 | 10.0 | 3 Jun 2025 |
| KPV Oral | X N/A | 1 | 8.4 | 8.4 | 8.4 | 17 Dec 2024 |
| NAD+ 100mg + Mots-C 10mg + 5-Amino 1MQ 10mg Blend | X N/A | 1 | 7.9 | 7.9 | 7.9 | 6 May 2025 |
| Oxytocin Acetate | X N/A | 1 | 8.8 | 8.8 | 8.8 | 2 Apr 2025 |
| Pinealon | X N/A | 1 | 8.3 | 8.3 | 8.3 | 6 May 2025 |
| Prostamax | X N/A | 1 | 10.0 | 10.0 | 10.0 | 27 Feb 2025 |
| PTD-DBM | X N/A | 1 | 7.3 | 7.3 | 7.3 | 24 Apr 2025 |
| Retatrutide 30mg Pen Kit | X N/A | 1 | 7.6 | 7.6 | 7.6 | 9 Jun 2025 |
| SNAP-8 | X N/A | 1 | 9.0 | 9.0 | 9.0 | 16 Mar 2025 |
| Stanozolol (Winstrol) Raw | X N/A | 1 | 9.1 | 9.1 | 9.1 | 8 Jul 2025 |
| Super Shred | X N/A | 1 | 9.8 | 9.8 | 9.8 | 14 Jan 2025 |
| TB-500 FRAG | X N/A | 1 | 7.1 | 7.1 | 7.1 | 16 Mar 2025 |
| Telmisartan | X N/A | 1 | 9.0 | 9.0 | 9.0 | 3 Jul 2025 |
| Test Base (No Ester) | X N/A | 1 | 8.2 | 8.2 | 8.2 | 28 Mar 2025 |
| Test Enanthate | X N/A | 1 | 7.8 | 7.8 | 7.8 | 7 May 2025 |
| Vilon | X N/A | 1 | 9.3 | 9.3 | 9.3 | 17 Dec 2024 |
Exhibit II
Evidence Log
41 LABORATORY RETURNS| Filed | Compound | Score | Claimed | Found | Δ Qty | Purity | Batch № | Lab | Source |
|---|---|---|---|---|---|---|---|---|---|
| 24 May 2026 | Adamax | 5.6 B | 10mg | 9.7mg | -2.9% | 98.63% | zfgzhq | Lab F | Community |
| 24 May 2026 | BAM15 | 7.1 A | 10mg | 9.9mg | -1.2% | 99.47% | c1b81p | Lab G | Community |
| 24 May 2026 | Retatrutide | 10.0 A | 36mg | (no batch claim) | 37.3mg | +3.6% | 99.90% | 3G361125 | Black Label / Gold Crimp / Clear Cap |
| 24 May 2026 | Hyaluronic acid | 10.0 A | 30mg | 28.5mg | -5.1% | 99.55% | vhk279 | Lab B | Community |
| 24 May 2026 | EAPA (ethyl alpha-phenylacetoacetate / ethyl 3-oxo-2-phenylbutanoate) CAS 5413-05-8 | 7.0 A | 5g | 4.8g | -3.1% | 98.57% | q9hpbn | Lab G | Public |
| 24 May 2026 | Retatrutide 30mg Pen Kit | 7.2 A | 30mg | 32.7mg | +9.1% | 98.39% | 2yll0r | Lab D | Public |
| 24 May 2026 | Retatrutide | 7.6 A | 10mg | (no batch claim) | 11.5mg | +15.0% | 99.90% | 3G101125 | Black Label / Silver Crimp / Clear Blue Cap |
| 24 May 2026 | Pinealon | 8.7 A | 15mg | 16.2mg | +8.0% | 96.33% | 46dvvw | Lab G | Community |
| 24 May 2026 | Oxytocin Acetate | 7.7 A | 20mg | 22.3mg | +11.3% | 99.79% | sla03d | Lab D | Public |
| 23 May 2026 | TB-500 FRAG | 7.8 A | 5mg | 4.8mg | -3.7% | 99.82% | dof1ez | Lab A | Public |
| 23 May 2026 | Telmisartan | 9.1 A | 50mg | 58.7mg | +17.3% | 99.93% | xc0xby | Lab C | Public |
| 21 May 2026 | Cerebrolysin | 9.2 A | 2mg | 2.3mg | +14.7% | 97.28% | h97c1r | Lab C | Public |
| 21 May 2026 | Test Base (No Ester) | 9.1 A | 100mg/ml | 104.4mg/ml | +4.4% | 97.00% | 6n9fj5 | Lab B | Community |
| 21 May 2026 | CJC-1295 With DAC | 9.6 A | 50mg | 50.6mg | +1.3% | 95.44% | dehqp7 | Lab D | Public |
| 21 May 2026 | Halotestin (Fluoxymesterone) | 7.6 A | 20mg | 24.0mg | +19.9% | 97.87% | 2j8xg4 | Lab G | Public |
| 20 May 2026 | Retatrutide | 7.0 A | 10mg | 11.3mgwebsite | 9.9mg | -12.2% | 99.90% | 3G101125 | Black Label / Silver Crimp / Clear Blue Cap |
| 20 May 2026 | Tirzepatide | 9.0 A | 10mg | 11.4mgpackage | 11.4mg | +0.3% | 99.69% | 2ZG101125 | Yellow Label / Silver Crimp / Yellow Cap |
| 20 May 2026 | Dianabol | 6.2 A | 100mg | 89.0mg | -11.0% | 99.96% | df2lgm | Lab E | Community |
| 20 May 2026 | NAD+ 100mg + Mots-C 10mg + 5-Amino 1MQ 10mg Blend | 8.3 A | 15mg | 16.5mg | +10.3% | 95.12% | cme2f7 | Lab F | Public |
| 20 May 2026 | Super Shred | 10.0 A | 300mg/ml | 335.9mg/ml | +12.0% | 96.48% | mtpdfh | Lab F | Public |
| 17 May 2026 | PTD-DBM | 6.6 A | 10mg | 9.5mg | -5.3% | 97.71% | 2xd3nb | Lab F | Community |
| 29 Jan 2026 | SNAP-8 | 8.0 A | 2mg | 1.9mg | -5.2% | 96.39% | r0ir7q | Lab G | Community |
| 9 Jan 2026 | GHRP-2 Acetate | 10.0 A | 30mg | 28.5mg | -5.2% | 97.79% | 79tnxy | Lab A | Community |
| 6 Jan 2026 | (2-Chloroethyl)benzene CAS 622-24-2 | 9.6 A | 10g | 9.8g | -1.7% | 95.32% | 4yl3wd | Lab B | Public |
| 29 Dec 2025 | Enclomiphene | 8.8 A | 25mg | 28.0mg | +12.1% | 97.36% | 18gtme | Lab C | Community |
| 29 Dec 2025 | EPO | 10.0 A | 10mg | 10.9mg | +8.7% | 98.63% | tc8vp8 | Lab B | Public |
| 12 Dec 2025 | ACE-031 | 7.9 A | 5mg | 5.1mg | +1.8% | 98.18% | s5t53k | Lab B | Community |
| 12 Dec 2025 | Anastrozole (Arimidex) Raw | 6.7 A | 100g | 87.3g | -12.7% | 96.18% | ree3bm | Lab A | Public |
| 5 Dec 2025 | Test Enanthate | 7.5 A | 300mg/ml | 306.7mg/ml | +2.2% | 96.66% | mqbb9o | Lab F | Public |
| 24 Nov 2025 | Tirzepatide | 9.2 A | 10mg | 11.6mglabel | 11.05mg | -5.0% | 99.58% | 2GTZ1019625 | Yellow Label / Silver Crimp / Yellow Cap |
| 23 Nov 2025 | Glutathione | 4.5 C | 50mg | 51.5mg | +3.1% | 99.68% | cr1mh8 | Lab B | Public |
| 23 Nov 2025 | Vilon | 10.0 A | 15mg | 17.7mg | +18.1% | 98.68% | a1ku9j | Lab B | Public |
| 17 Nov 2025 | Cagrilintide 5mg + Semaglutide 5mg Blend | 7.1 A | 20mg | 19.3mg | -3.3% | 95.64% | zetua5 | Lab A | Public |
| 5 Nov 2025 | KissPeptin-10 | 9.9 A | 30mg | 35.1mg | +17.1% | 97.29% | 12tgb9 | Lab C | Community |
| 5 Nov 2025 | KPV Oral | 8.9 A | 25mg | 21.3mg | -14.6% | 95.47% | bucf55 | Lab C | Public |
| 4 Nov 2025 | Stanozolol (Winstrol) Raw | 7.8 A | 100g | 105.1g | +5.1% | 95.78% | 2wbkc6 | Lab E | Public |
| 9 Oct 2025 | IGF-1 LR3 | 9.2 A | 5mg | 4.6mg | -7.6% | 97.20% | km3ly2 | Lab C | Community |
| 3 Oct 2025 | 1-Boc-4-AP (tert-butyl 4-(phenylamino)piperidine-1-carboxylate) CAS 125541-22-2 | 8.4 A | 10g | 11.6g | +16.3% | 96.17% | crzlyy | Lab B | Public |
| 3 Oct 2025 | Adipotide | 9.3 A | 50mg | 43.7mg | -12.6% | 97.88% | ojb57m | Lab B | Public |
| 3 Oct 2025 | GLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg | 5.0 B | 5mg | 5.3mg | +5.8% | 99.61% | ih7pdv | Lab C | Public |
| 3 Oct 2025 | Prostamax | 9.8 A | 20mg | 24.7mg | +23.5% | 99.58% | yec12i | Lab F | Community |
— END OF EVIDENCE LOG —